Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Charlotte, North Carolina

CNS medication trials in Charlotte, NC

22 CNS medication studies are recruiting participants at sites in Charlotte as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Charlotte at a glance

Depression studies recruiting in Charlotte

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    New Hope Clinical Research
    Registry record
    NCT07226661 · updated
  2. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  3. A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07196501 · updated
  4. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06830044 · updated
  5. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06963021 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Charlotte, NC on ClinicalTrials.gov.

Schizophrenia studies recruiting in Charlotte

  1. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    New Hope Clinical Research
    Registry record
    NCT06540833 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Charlotte, NC on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Charlotte

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Novant Health Weisiger Cancer Insititute ( Site 0266)
    Registry record
    NCT06623422 · updated
  2. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  3. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Levine Cancer Institute ( Site 0014)
    Registry record
    NCT06312176 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Charlotte, NC on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Charlotte

  1. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial SiteCharlotte
    Registry record
    NCT05877963 · updated
  2. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Atrium Health
    Registry record
    NCT07225504 · updated
  3. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Sanofi
    Study site
    Piedmont HealthCare - Lake Norman Neurology- Site Number : 8400002
    Registry record
    NCT07325292 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Charlotte, NC on ClinicalTrials.gov.

Epilepsy studies recruiting in Charlotte

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study sites
    Atrium Health · Onsite Clinical Solutions, LLC
    Registry record
    NCT05667142 · updated
  2. An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

    • Phase 3
    • Ages 2 to 55
    • All sexes
    Sponsor
    Epygenix
    Study sites
    Atrium Health STRIVE Research · On-Site Clinical Solution
    Registry record
    NCT05066217 · updated
  3. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    OnSite Clinical Solutions, LLC
    Registry record
    NCT06798896 · updated
  4. Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

    • Phase 1
    • Ages 18 to 70
    • All sexes
    Sponsor
    Suninflam Inc
    Study site
    OnSite Clinical Solutions, LLC
    Registry record
    NCT07051629 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Charlotte, NC on ClinicalTrials.gov.

Migraine studies recruiting in Charlotte

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study sites
    Onsite Clinical Solutions Ballantyne · Onsite Clinical Solutions Mecklenburg · Onsite Clinical Solutions Park Cedar Dr.
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    OnSite Clinical Solutions
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    OnSite Clinical Solutions
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    OnSite Clinical Solutions, LLC
    Registry record
    NCT04649242 · updated
  5. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    OnSite Clinical Solutions, LLC
    Registry record
    NCT04743141 · updated
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Onsite Clinical Solutions - Don Lochman Lane - Charlotte /ID# 282834
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Charlotte, NC on ClinicalTrials.gov.

Ask about studies near Charlotte

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call